Pharming creates sustainable long-term value by leveraging its core strengths in clinical development and rare-disease drug commercialization. To sustain longer-term growth, we continue to build a risk-balanced portfolio while taking on more development activities. To further build out our rare disease portfolio, Pharming is pursuing a strategy focused on in-licensing or the acquisition of clinical stage assets. We have proven these capabilities and already launched our second commercial product, Joenja® (leniolisib) for APDS* in the US, which we licensed from Novartis.
Pharming’s business development and licensing group seeks partners whose mission and core values align with Pharming’s commitment to serve rare disease patients. Our team searches for clinical and commercial stage assets in immunology, hematology, respiratory, gastroenterology and beyond.
Contact our BD team
Meet our Business Development team at major industry conferences and partnering meetings. Please contact us at bd@pharming.com.